Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT
Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT
Recruiting · NCT05623267 · Registry updated 2023-08-07Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT | Neoplasm, Residual, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, neoplasm | Recruiting | Phase 2 / Phase 3 | 2023-08-07 | NCT05623267 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Sun Yat-sen University | 606 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Sun Yat-sen University Cancer Center | Guangzhou | China | 315 |